ALLO - Allogene Therapeutics GAAP EPS of -$0.68 misses by $0.06 revenue of $0.05M beats by $0.04M

2023-05-03 16:35:34 ET

• Allogene Therapeutics press release ( NASDAQ: ALLO ): Q1 GAAP EPS of -$0.68 misses by $0.06 .
• Revenue of $0.05M (-16.7% Y/Y) beats by $0.04M .
• Research and development expenses were $80.2 million for the first quarter of 2023, which includes $9.2 million of non-cash stock-based compensation expense.
• General and administrative expenses were $18.9 million for the first quarter of 2023, which includes $9.6 million of non-cash stock-based compensation expense.
• The Company had $514 million in cash, cash equivalents, and investments as of March 31, 2023.
• 2023 Financial Guidance
• The Company now expects a decrease in cash, cash equivalents, and investments of approximately $230 million in 2023.

For further details see: